189 related articles for article (PubMed ID: 29435360)
21. Two-year abatacept retention rate in clinical practice in the French ACTION cohort.
Mariette X; Schaeverbeke T; Gaudin P; Chartier M; Heitzmann J; Vannier-Moreau V; Hilliquin P; Cantagrel A
Joint Bone Spine; 2019 Nov; 86(6):753-759. PubMed ID: 31352138
[TBL] [Abstract][Full Text] [Related]
22. A budget impact analysis for making treatment decisions based on anti-cyclic citrullinated peptide (anti-CCP) testing in rheumatoid arthritis.
Park SH; Han X; Lobo F; Kratochvil D; Patel D
J Med Econ; 2020 Jun; 23(6):624-630. PubMed ID: 32075453
[No Abstract] [Full Text] [Related]
23. Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis.
Ogawa N; Ohashi H; Ota Y; Kobori K; Suzuki M; Tsuboi S; Hayakawa M; Goto Y; Karahashi T; Kimoto O; Miyamoto T; Furukawa S; Shimoyama K; Suzuki D; Maekawa Y
Immunol Med; 2019 Mar; 42(1):29-38. PubMed ID: 31067155
[TBL] [Abstract][Full Text] [Related]
24. Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA.
Harrold LR; Connolly SE; Wittstock K; Zhuo J; Kelly S; Lehman T; Shan Y; Rebello S; Guo L; Khaychuk V
Rheumatol Ther; 2022 Apr; 9(2):465-480. PubMed ID: 34940957
[TBL] [Abstract][Full Text] [Related]
25. Two-year treatment persistence with subcutaneous abatacept in rheumatoid arthritis: results from the French cohort of the ASCORE study.
Flipo RM; Constantin A; Goupille P; Chartier M; Ohayon A; Mariette X
Clin Exp Rheumatol; 2024 Mar; ():. PubMed ID: 38436358
[TBL] [Abstract][Full Text] [Related]
26. Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study.
Alemao E; Guo Z; Frits ML; Iannaccone CK; Shadick NA; Weinblatt ME
Semin Arthritis Rheum; 2018 Apr; 47(5):630-638. PubMed ID: 29241640
[TBL] [Abstract][Full Text] [Related]
27. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial.
Sokolove J; Schiff M; Fleischmann R; Weinblatt ME; Connolly SE; Johnsen A; Zhu J; Maldonado MA; Patel S; Robinson WH
Ann Rheum Dis; 2016 Apr; 75(4):709-14. PubMed ID: 26359449
[TBL] [Abstract][Full Text] [Related]
28. Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis: Post hoc analysis of a multicentre, real-world observational study in Japan (ORIGAMI).
Misaki K; Tamura N; Azuma T; Shinoda K; Tanaka M; Fujiwara H; Tsuboi H; Kasama T; Yoshimi R; Hanyu T; Kusaka Y; Hirao M; Onishi M; Uchino A; Izumiyama T; Yang KS; Ogawa N; Matsui K; Kurasawa K; Kawaai S; Yasuoka H; Okumura N; Ueda Y; Tanaka E; Inoue E; Tsuritani K; Matsumoto S; Yamanaka H; Harigai M
Mod Rheumatol; 2024 Feb; 34(2):297-306. PubMed ID: 37233722
[TBL] [Abstract][Full Text] [Related]
29. Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA).
Iannone F; Courvoisier DS; Gottenberg JE; Hernandez MV; Lie E; Canhão H; Pavelka K; Hetland ML; Turesson C; Mariette X; Choquette D; Finckh A
Clin Rheumatol; 2017 Apr; 36(4):773-779. PubMed ID: 27966068
[TBL] [Abstract][Full Text] [Related]
30. Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors.
Han X; Lobo F; Broder MS; Chang E; Gibbs SN; Ridley DJ; Yermilov I
J Health Econ Outcomes Res; 2021 May; 8(1):71-78. PubMed ID: 34046511
[No Abstract] [Full Text] [Related]
31. Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the 'ORA' registry.
Nourisson C; Soubrier M; Mulliez A; Baillet A; Bardin T; Cantagrel A; Combe B; Dougados M; Flipo RM; Schaeverbeke T; Sibilia J; Vittecoq O; Ravaud P; Gottenberg JE; Mariette X; Tournadre A
RMD Open; 2017; 3(2):e000515. PubMed ID: 29177081
[TBL] [Abstract][Full Text] [Related]
32. Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry.
Lin CT; Huang WN; Tsai WC; Chen JP; Hung WT; Hsieh TY; Chen HH; Hsieh CW; Lai KL; Tang KT; Tseng CW; Chen DY; Chen YH; Chen YM
PLoS One; 2021; 16(4):e0250877. PubMed ID: 33930048
[TBL] [Abstract][Full Text] [Related]
33. Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study.
Alten R; Nüßlein H; Galeazzi M; Lorenz HM; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Pavelka K; Chartier M; Poncet C; Rauch C; Elbez Y; Le Bars M
RMD Open; 2016; 2(1):e000228. PubMed ID: 26925253
[TBL] [Abstract][Full Text] [Related]
34. Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study.
Matsubara T; Inoue H; Nakajima T; Tanimura K; Sagawa A; Sato Y; Osano K; Nagano S; Ueki Y; Hanyu T; Hashizume K; Amano N; Tanaka Y; Takeuchi T
RMD Open; 2018; 4(2):e000813. PubMed ID: 30622737
[TBL] [Abstract][Full Text] [Related]
35. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.
Gottenberg JE; Courvoisier DS; Hernandez MV; Iannone F; Lie E; Canhão H; Pavelka K; Hetland ML; Turesson C; Mariette X; Finckh A
Arthritis Rheumatol; 2016 Jun; 68(6):1346-52. PubMed ID: 26815727
[TBL] [Abstract][Full Text] [Related]
36. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors.
Westhovens R; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Helfrick R; Bathon J
Ann Rheum Dis; 2009 Dec; 68(12):1870-7. PubMed ID: 19124524
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE).
Fleischmann R; Weinblatt M; Ahmad H; Maldonado MA; Alemao E; Ye J; Schiff M
Rheumatol Ther; 2019 Dec; 6(4):559-571. PubMed ID: 31642045
[TBL] [Abstract][Full Text] [Related]
38. Subcutaneous abatacept in rheumatoid arthritis: A real-life experience.
Sarmiento-Monroy JC; Parada-Arias L; Rodríguez-López M; Rodríguez-Jiménez M; Molano-González N; Rojas-Villarraga A; Mantilla RD
J Transl Autoimmun; 2019 Dec; 2():100016. PubMed ID: 32743504
[TBL] [Abstract][Full Text] [Related]
39. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
[TBL] [Abstract][Full Text] [Related]
40. Significance of anti-Ro/SSA antibodies in the response and retention of abatacept in patients with rheumatoid arthritis: a multicentre cohort study.
Endo Y; Koga T; Kawashiri SY; Morimoto S; Nishino A; Okamoto M; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Tsuru T; Nagano S; Arinobu Y; Hidaka T; Tada Y; Kawakami A
Scand J Rheumatol; 2021 Jan; 50(1):15-19. PubMed ID: 32880228
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
